Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q6)Jun 30, 2025 | (FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 84.05%319.44M | 192.58%640.08M | 27.18%173.56M | 31.12%218.77M | 154.75%136.47M | 14.26%166.85M | --53.57M | --146.02M | ---- | ---- |
| Operating income | 84.05%319.44M | 192.58%640.08M | 27.18%173.56M | 31.12%218.77M | 154.75%136.47M | 14.26%166.85M | 53.57M | 146.02M | ||
| Cost of sales | -1.46%-31.26M | -9.19%-60.32M | 7.11%-30.81M | -24.95%-55.24M | -123.79%-33.17M | -1,359.94%-44.21M | ---14.82M | ---3.03M | ---- | ---- |
| Operating expenses | -1.46%-31.26M | -9.19%-60.32M | 7.11%-30.81M | -24.95%-55.24M | -123.79%-33.17M | -1,359.94%-44.21M | -14.82M | -3.03M | ||
| Gross profit | 101.87%288.18M | 254.52%579.77M | 38.19%142.75M | 33.35%163.54M | 166.59%103.3M | -14.23%122.64M | 38.75M | 142.99M | ||
| Administrative expenses | 0.75%-34.38M | 5.96%-74.61M | -4.18%-34.64M | 8.57%-79.34M | 24.61%-33.24M | -12.32%-86.77M | -15.65%-44.1M | 1.22%-77.25M | 6.03%-38.13M | 33.57%-78.21M |
| Research and development expenses | -30.14%-253.16M | 0.83%-404.15M | 0.08%-194.53M | 12.97%-407.52M | 10.04%-194.68M | 2.73%-468.24M | 6.70%-216.4M | -45.32%-481.36M | -73.45%-231.95M | -98.76%-331.24M |
| Special items of operating profit | -47.16%24.88M | -39.75%75.26M | -48.68%47.08M | 3.36%124.91M | 7.52%91.73M | 637.64%120.86M | 853.12%85.31M | 352.41%16.38M | -88.53%8.95M | -164.61%-6.49M |
| Operating profit | 164.88%25.52M | 188.84%176.27M | -19.57%-39.33M | 36.31%-198.41M | 75.89%-32.9M | 21.97%-311.52M | 47.75%-136.43M | 4.02%-399.24M | -171.17%-261.13M | 49.83%-415.94M |
| Financing cost | 29.09%-3.95M | 18.52%-9.92M | 20.15%-5.56M | 14.27%-12.18M | 35.94%-6.97M | -7.77%-14.21M | -74.38%-10.88M | -11.47%-13.18M | 8.33%-6.24M | -227.95%-11.83M |
| Earning before tax | 148.06%21.58M | 178.99%166.34M | -12.63%-44.9M | 35.35%-210.59M | 72.94%-39.86M | 21.02%-325.72M | 44.90%-147.31M | 3.59%-412.42M | -159.32%-267.36M | 48.63%-427.77M |
| After-tax profit from continuing operations | 148.06%21.58M | 178.99%166.34M | -12.63%-44.9M | 35.35%-210.59M | 72.94%-39.86M | 21.02%-325.72M | 44.90%-147.31M | 3.59%-412.42M | -159.32%-267.36M | 48.63%-427.77M |
| Earning after tax | 148.06%21.58M | 178.99%166.34M | -12.63%-44.9M | 35.35%-210.59M | 72.94%-39.86M | 21.02%-325.72M | 44.90%-147.31M | 3.59%-412.42M | -159.32%-267.36M | 48.63%-427.77M |
| Profit attributable to shareholders | 148.06%21.58M | 178.99%166.34M | -12.63%-44.9M | 35.35%-210.59M | 72.94%-39.86M | 21.02%-325.72M | 44.90%-147.31M | 3.59%-412.42M | -159.32%-267.36M | 48.63%-427.77M |
| Basic earnings per share | 140.00%0.02 | 177.27%0.17 | -25.00%-0.05 | 37.14%-0.22 | 75.00%-0.04 | 20.45%-0.35 | 44.83%-0.16 | 4.35%-0.44 | -163.64%-0.29 | 70.32%-0.46 |
| Diluted earnings per share | 140.00%0.02 | 177.27%0.17 | -25.00%-0.05 | 37.14%-0.22 | 75.00%-0.04 | 20.45%-0.35 | 44.83%-0.16 | 4.35%-0.44 | -163.64%-0.29 | 70.32%-0.46 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
| Audit Opinions | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion |
| Auditor | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants | -- | Deloitte Guan Huang Chen Fang Certified Public Accountants |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.